REZUROCK Drug Patent Profile

When do Rezurock patents expire, and what generic alternatives are available?

Rezurock is a drug marketed by Kadmon Pharms Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in twenty-nine countries.

The generic ingredient in REZUROCK is belumosudil mesylate. One supplier is listed for this compound. Additional details are available on the belumosudil mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rezurock

Rezurock was eligible for patent challenges on July 16, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 16, 2028. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for REZUROCK

International Patents:	57
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	8
Patent Applications:	5
Drug Prices:	Drug price information for REZUROCK
What excipients (inactive ingredients) are in REZUROCK?	REZUROCK excipients list
DailyMed Link:	REZUROCK at DailyMed

See drug prices for REZUROCK

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for REZUROCK

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY

NDA:

214783

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for REZUROCK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Methodist Hospital Research Institute	PHASE2
Sanofi	Phase 3
Kadmon, a Sanofi Company	Phase 2

See all REZUROCK clinical trials

Paragraph IV (Patent) Challenges for REZUROCK

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REZUROCK	Tablets	belumosudil mesylate	200 mg	214783	3	2025-07-16

US Patents and Regulatory Information for REZUROCK

REZUROCK is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kadmon Pharms Llc	REZUROCK	belumosudil mesylate	TABLET;ORAL	214783-001	Jul 16, 2021		RX	Yes	Yes
Kadmon Pharms Llc	REZUROCK	belumosudil mesylate	TABLET;ORAL	214783-001	Jul 16, 2021		RX	Yes	Yes
Kadmon Pharms Llc	REZUROCK	belumosudil mesylate	TABLET;ORAL	214783-001	Jul 16, 2021		RX	Yes	Yes
Kadmon Pharms Llc	REZUROCK	belumosudil mesylate	TABLET;ORAL	214783-001	Jul 16, 2021		RX	Yes	Yes
Kadmon Pharms Llc	REZUROCK	belumosudil mesylate	TABLET;ORAL	214783-001	Jul 16, 2021		RX	Yes	Yes			Y	Y
Kadmon Pharms Llc	REZUROCK	belumosudil mesylate	TABLET;ORAL	214783-001	Jul 16, 2021		RX	Yes	Yes

International Patents for REZUROCK

See the table below for patents covering REZUROCK around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2549397
Denmark	2903618
Canada	3178096
Eurasian Patent Organization	022875	ПРОИЗВОДНЫЕ 4-(ИНДАЗОЛ-5-ИЛ-АМИНО)-2-ФЕНИЛХИНАЗОЛИНА (4-(INDAZOLE-5-YLAMINO)-2-PHENYLQUINAZOLIN DERIVATIVES)
Eurasian Patent Organization	200702048	ФАРМАКОКИНЕТИЧЕСКИ УЛУЧШЕННЫЕ СОЕДИНЕНИЯ
Japan	2015533125	ＲＨＯキナーゼ阻害剤

Supplementary Protection Certificates for REZUROCK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2903618	SPC/GB22/068	United Kingdom		PRODUCT NAME: BELUMOSUDIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK PLGB 53904/0001-0001 20220707

Rezurock (ropeginterferon?) Market Dynamics and Financial Trajectory: Exclusivity, Competitive Entry Risk, and Revenue Outlook

Last updated: May 30, 2026

Rezurock (ustekinumab? no) is upadacitinib? no. Rezurock is belumosudil (KD: Ruxolitinib?). The drug is belumosudil (Rezurock), an oral ROCK2 inhibitor for chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adults and pediatric patients 12 years and older. The financial trajectory is driven by (1) premium pricing and label expansion, (2) adoption constraints from line-of-therapy requirements, (3) competitive pressure from JAK inhibitors and other late-line cGVHD agents, and (4) generic/biosimilar entry risk that is typically limited because the product is a small-molecule, not a biologic.

Market dynamics for Rezurock (belumosudil): what drives adoption in chronic GVHD

Featured snippet answer: Rezurock’s uptake is concentrated in late-line cGVHD due to its positioning after multiple systemic failures, supported by durable response signals and an expanding patient base through label language and real-world sequencing. Uptake is constrained by competitive alternatives (other kinase inhibitors and investigational therapies) and payer restrictions tied to line-of-therapy and prior-treatment criteria.

Why the late-line positioning matters commercially

Rezurock’s commercial “gravity” is tied to the cGVHD treatment algorithm:

• Patients generally transition to additional systemic options after corticosteroid dependence, intolerance, or failure of prior immunosuppressants.
• Rezurock is marketed as an option after at least two prior systemic therapies (adult and pediatric 12+), which typically improves access once earlier regimens are exhausted.
• Late-line status can protect near-term revenues from early-step competitors, but it can also cap TAM if payers narrow reimbursement.

Real-world adoption bottlenecks

Key adoption friction points for oral late-line cGVHD therapy:

• Prior therapy documentation: reimbursement often requires proof of at least two prior systemic lines.
• Switching inertia: clinicians may continue steroids or switch to other established kinase inhibitors rather than change class.
• Monitoring and tolerability profile: oral agents increase switching if tolerability is manageable, but any adverse-event burden increases discontinuation rates.

Pricing and net-to-gross dynamics

Rezurock’s revenue performance is typically shaped by:

• rebate intensity in specialty channels,
• patient-level contracting (e.g., co-pay support),
• and payer step edits tied to line-of-therapy or response thresholds.

When does Rezurock lose exclusivity? What patent expiration dates govern generics risk

Featured snippet answer: Rezurock is protected by a layered small-molecule patent estate. Generic entry timing is governed by the latest composition-of-matter patents and any additional formulation, method-of-use, and combination patents, plus regulatory exclusivity (if any) and patent term adjustments in the relevant jurisdictions.

Patent estate structure that typically controls entry

For an orally administered small molecule like belumosudil, the relevant IP layers are usually:

• Composition of matter (core risk for generic substitution).
• Polymorph/crystal form or particle engineering claims (formulation risk).
• Methods of treatment specific to cGVHD populations and treatment lines (enforcement leverage for label-tied substitutions).
• Combination regimens if claimed.

How to read the exclusivity timeline for a small molecule

For generics, exclusivity is rarely a single date. A practical entry model uses:

• the first expiring patent (often impacts some manufacturing “workarounds” but not full generic legal risk),
• the last expiring claim that blocks marketing,
• and whether any litigation or injunctions affect FDA approval or launch.

(No patent expiration dates were provided in the prompt. A complete, accurate date table cannot be produced without external patent/IP and regulatory database data.)

What is the Orange Book status of Rezurock and when can FDA approve generics

Featured snippet answer: Rezurock’s generic risk depends on Orange Book-listed patents tied to the NDA reference drug. FDA can approve a generic via Paragraph IV only if it certifies against the listed patents and prevails in litigation or reaches settlement terms permitting approval/launch.

What Paragraph IV would target for belumosudil

For late-line cGVHD small-molecule brands, Paragraph IV challenges commonly target:

• the composition of matter patents,
• sometimes formulation/polymorph patents if those are the last remaining barriers,
• and method-of-use patents if tied tightly to the label.

How Orange Book listings translate into launch timing

Once an FDA generic application is accepted:

• an automatic 30-month stay can delay approval (if the challenge is timely and triggers the statutory stay),
• settlements can shift launch to a mutually agreed date,
• and court rulings can eliminate the stay or preserve it depending on patent validity/infringement outcomes.

(Orange Book identifiers and patent listing numbers were not included. Without those, a correct status statement and launch date modeling cannot be produced.)

How does Rezurock compare with cGVHD competitors: JAK inhibitors and other late-line options

Featured snippet answer: Rezurock competes in late-line cGVHD where physicians select based on speed of response, steroid-sparing potential, tolerability, and prior-treatment history. Its oral, kinase-targeted profile and durability of response are key differentiators, but competitive outcomes depend on head-to-head data, cross-trial endpoints, and real-world discontinuation rates.

Key competitive set (commercially relevant categories)

Rezurock’s competitive pressure typically comes from:

• JAK inhibitors used in immune-mediated diseases and sometimes adopted in cGVHD practice patterns,
• other late-line immunomodulators and kinase inhibitors under development or with existing approvals,
• and standard-of-care steroids with steroid-sparing alternatives.

What matters in payer and formulary decisions

Formulary adoption tends to weigh:

• clinical endpoint durability (response maintenance),
• steroid reduction rates,
• adverse-event management cost,
• and patient persistence.

What patent litigation affects Rezurock and does it change generic entry risk

Featured snippet answer: Patent litigation affects generic timing only if it involves Orange Book-listed patents tied to the NDA and results in court injunctions or settlement agreements that control the FDA approval date or permitted commercial launch date.

Why cGVHD small molecules tend to see clustered disputes

For specialty brands with late-line label restrictions:

• litigations concentrate on the newest blocking patents (often last composition-of-matter or key method-of-use claims),
• and settlements often include launch-date carve-outs to avoid prolonged appeals.

(No litigation docket data or case identifiers were provided in the prompt. A litigation-specific section with dates and outcomes cannot be produced accurately.)

Rezurock biosimilar risk: is there any biologic-style exclusivity threat

Featured snippet answer: No. Rezurock is a small-molecule drug (belumosudil), so the biologics framework does not apply. The relevant threat is generic chemical substitution, not biosimilar development.

What “high-level exclusivity” looks like for small molecules

• No biosimilar pathways under the BPCIA.
• Generic chemical copies must navigate composition-of-matter and patent-for-practice barriers.

Formulation and method-of-use patents: what IP layers protect Rezurock beyond the active ingredient

Featured snippet answer: For small-molecule cGVHD therapy, non-core protection often covers specific drug forms (e.g., solid-state variants) and label-tied treatment methods (e.g., cGVHD in defined lines of therapy or patient subsets).

Common formulation patent themes for oral small molecules

• crystalline forms and polymorphs,
• amorphous mixtures,
• particle size or dissolution-rate modifications,
• manufacturing processes that achieve defined specs.

How method-of-use claims can constrain “off-label” substitutions

Method-of-use claims can:

• discourage generic launch if FDA-approved label is tied to protected treatment populations,
• enable brand enforcement against “induced infringement” or label-based promotion.

(No specific Rezurock patent numbers were provided, so an accurate inventory of formulation and method-of-use patents cannot be produced.)

Financial trajectory for Rezurock (belumosudil): what typically drives revenue ramp, plateau, and decline

Featured snippet answer: Revenue typically follows a ramp from initial cGVHD approval through subsequent label expansion and formulary penetration, then plateaus as adoption saturates within late-line patients, and declines if competitors expand or if real-world persistence weakens. Generic risk in this class is driven primarily by patent expiration and litigation outcomes.

Revenue drivers

1. Patient pool growth

   • expansion to additional age groups,
   • broader prior-therapy language where applicable,
   • real-world clinician adoption.

2. Persistence and discontinuation

   • oral kinase inhibitors can show durable responses, but discontinuation from adverse events or insufficient response affects lifetime revenue per patient.

3. Net price

   • specialty rebates and contract dynamics can compress growth even when volume rises.

4. 競争 (competitive dynamics)

   • additional approved agents can shift physician preference and reduce marginal uptake.

Key metrics to track for trajectory (investor-useful)

• Prescriptions or scripts (monthly/quarterly).
• Total treated patient counts and persistence curves.
• Channel inventory trends.
• Net sales vs gross-to-net conversion.
• Share of late-line cGVHD formulary coverage.

(The prompt asks for financial trajectory but does not include actual historical revenue figures, guidance, or analyst estimates. Without those, a data-backed trajectory cannot be correctly quantified.)

Revenue exposure by geography and payer segment

Featured snippet answer: Rezurock’s revenue exposure is concentrated in geographies where specialty reimbursement supports late-line cGVHD kinase therapy access. Payer mix (commercial vs Medicare/Medicaid vs hospital-based) shifts net realization via rebate and prior authorization intensity.

How to model net sales sensitivity

• Rebate intensity affects net price more than list price.
• Prior authorization reduces “immediate” uptake after a physician decision.
• Hospital formularies drive uptake in academic centers, then community penetration follows.

(No regional revenue breakdown was provided, so geographic exposure cannot be quantified.)

Generic entry scenarios for Rezurock: what can delay launch besides patents

Featured snippet answer: Even with patent expiration, generic launch can be delayed by Orange Book listing status, patent litigation outcomes, settlement terms, FDA CMC readiness, and manufacturing scale-up.

Scenario framework used by market strategists

• Best-case for generics: early patent wins, no stay, immediate FDA approval, rapid launch.
• Base-case: approval after statutory stay or settlement, slower ramp.
• Worst-case: brand wins key patents, launch is blocked or pushed.

(Accurate scenario dates require patent and Orange Book data.)

Key Takeaways

• Rezurock’s commercial dynamics are driven by late-line cGVHD positioning, payer access rules, and persistence.
• Because it is a small molecule, the generic threat is the main long-term exclusivity risk; there is no biosimilar framework.
• Generic timing depends on Orange Book-listed patents and any Paragraph IV litigation or settlements.
• A quantifiable financial trajectory and exclusivity calendar require specific Orange Book and patent expiration data that were not included in the prompt.

FAQs

1. What patient subgroups drive Rezurock uptake in chronic GVHD?
2. How do prior-line requirements affect Rezurock reimbursement and prescription volume?
3. Which patent categories most often block generic belumosudil approval?
4. Do settlements in Paragraph IV cases typically control Rezurock launch dates or only FDA approval timing?
5. What real-world persistence rates matter most for long-run Rezurock sales?

References (APA)

No sources were cited because the prompt did not provide drug/regulatory identifiers, Orange Book listings, patent numbers, litigation records, or financial historical data required for an accurate, cited market and financial analysis.